MK-1200

BIOLOGICAL2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Advanced Solid TumorsAdvanced solid tumor

Phase 1

Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)

CompletedNCT06242691

Merck Sharp & Dohme LLCAdvanced Solid Tumors

Start: 2024-02-28End: 2025-06-17Updated: 2026-03-06

A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants with Advanced Solid Tumors

CompletedCTIS2023-508684-68-00

Merck Sharp & Dohme LLCAdvanced solid tumor

End: 2024-07-30Target: 62Updated: 2024-06-28